Jeffrey Goldstein, MD
Interventional Cardiology · Bloomington, ILNPI 1689756900
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $5,813 of the $9,601 with a category attached, or 60.5%. Medtronic accounts for 74.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $6,151 and has fallen 92.1% since, to $487 in 2025.
Across 120 payments — averaging $80.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Boston Scientific$1K
- Abbott$420
- Amgen$242
- Edwards Lifesciences$230
- Shockwave Medical, Inc$77
- plus $472 from 14 others
Across 240 payments — averaging $1192.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$125K
- Boston Scientific$75K
- Bard Peripheral Vascular, Inc.$42K
- Edwards Lifesciences$18K
- Surmodics, Inc.$16K
- Intact Vascular, Inc.$6K
- plus $4K from 3 others
What the payments were for
- Speaking & faculty fees$5,81361%
- Food & beverage$3,74639%
- Gifts$420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 40 | $7,128 |
| Boston Scientific | 21 | $1,032 |
| Abbott | 11 | $420 |
| Amgen | 14 | $242 |
| Edwards Lifesciences | 5 | $230 |
| Shockwave Medical, Inc | 1 | $77 |
| Johnson & Johnson | 4 | $76 |
| AstraZeneca | 4 | $60 |
| Novartis | 3 | $56 |
| Welch Allyn | 1 | $42 |
| E.r. Squibb & Sons, L.L.C. | 3 | $38 |
| W. L. Gore & Associates, Inc. | 2 | $36 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $34 |
| Pfizer | 2 | $26 |
| Cardiovascular Systems Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
| Abiomed | 1 | $15 |
| Biotronik Inc. | 1 | $14 |
| Getinge USA Sales, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,601 in reported general payments places this provider in the 55th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 268 | $279,400 |
| EntrestoSacubitril/Valsartan | 262 | $254,751 |
| BrilintaTicagrelor | 64 | $61,331 |
| XareltoRivaroxaban | 45 | $48,730 |
| Repatha SureclickEvolocumab | 22 | $26,552 |
| Praluent PenAlirocumab | 23 | $16,057 |
| FarxigaDapagliflozin Propanediol | 12 | $12,179 |
| Metoprolol Succinate | 528 | $6,596 |
| ClopidogrelClopidogrel Bisulfate | 599 | $5,547 |
| Atorvastatin Calcium | 358 | $3,363 |
| Potassium Chloride | 122 | $2,997 |
| Digoxin | 60 | $1,688 |
| Metolazone | 47 | $1,647 |
| Losartan Potassium | 205 | $1,639 |
| Ranolazine ErRanolazine | 16 | $1,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $26 | $279,400268 claims |
| NovartisEntresto | $56 | $254,751262 claims |
| AstraZenecaBrilinta, Farxiga | $60 | $73,51076 claims |
| Johnson & JohnsonXarelto | $76 | $48,73045 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Bloomington
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
- Jaafer GolzarOak Lawn$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.